Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roula Tsonaka

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Ophthalmology. Retina|April 26, 2022
Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy PatientsHelena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
Scientific Reports|June 5, 2024
Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 diseaseKrista E van Meijgaarden, Suzanne van Veen, Roula Tsonaka, et al.
Journal of Medical Virology|July 9, 2026
Tracking COVID-19 Severity and Progression Through Amines and Lipid MediatorsMelissa Goris, Merys Valdez, Lieke Lamont, et al.
Clinical Proteomics|June 5, 2026
Quantitative tandem mass tag-based serum proteomics for longitudinal biomarker monitoring in Duchenne muscular dystrophyAhmed Naveed, Elissa Recinos, Dexter Chow, et al.
Acta Ophthalmologica|February 12, 2026
Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4Helena M A Feenstra, Issam El Mansori, Thomas J van Rijssen, et al.
Diseases of the Colon and Rectum|March 15, 2019
Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT TrialMaxime J M van der Valk, Denise E Hilling, Elma Meershoek-Klein Kranenbarg, et al.
American Journal of Ophthalmology|July 2, 2021
Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled TrialThomas J van Rijssen, Elon H C van Dijk, Roula Tsonaka, et al.
Journal of Neuromuscular Diseases|June 3, 2026
MDBiomarkers: A queryable biomarkers database integrating multiple serum and tissue datasets for Duchenne muscular dystrophyWangshu Tu, Rebecca A Tobin, Leenah Abdelrazeq, et al.
American Journal of Ophthalmology|April 15, 2020
Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE TrialThomas J van Rijssen, Elon H C van Dijk, Paula Scholz, et al.
American Journal of Ophthalmology|November 14, 2020
Reply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous ChorioretinopathyThomas J van Rijssen, Elon H C van Dijk, Greet Dijkman, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Ophthalmology. Retina|April 26, 2022
Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy PatientsHelena M A Feenstra, Elon H C van Dijk, Thomas J van Rijssen, et al.
Scientific Reports|June 5, 2024
Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 diseaseKrista E van Meijgaarden, Suzanne van Veen, Roula Tsonaka, et al.
Journal of Medical Virology|July 9, 2026
Tracking COVID-19 Severity and Progression Through Amines and Lipid MediatorsMelissa Goris, Merys Valdez, Lieke Lamont, et al.
Clinical Proteomics|June 5, 2026
Quantitative tandem mass tag-based serum proteomics for longitudinal biomarker monitoring in Duchenne muscular dystrophyAhmed Naveed, Elissa Recinos, Dexter Chow, et al.
Acta Ophthalmologica|February 12, 2026
Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4Helena M A Feenstra, Issam El Mansori, Thomas J van Rijssen, et al.
Diseases of the Colon and Rectum|March 15, 2019
Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT TrialMaxime J M van der Valk, Denise E Hilling, Elma Meershoek-Klein Kranenbarg, et al.
American Journal of Ophthalmology|July 2, 2021
Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled TrialThomas J van Rijssen, Elon H C van Dijk, Roula Tsonaka, et al.
Journal of Neuromuscular Diseases|June 3, 2026
MDBiomarkers: A queryable biomarkers database integrating multiple serum and tissue datasets for Duchenne muscular dystrophyWangshu Tu, Rebecca A Tobin, Leenah Abdelrazeq, et al.
American Journal of Ophthalmology|April 15, 2020
Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE TrialThomas J van Rijssen, Elon H C van Dijk, Paula Scholz, et al.
American Journal of Ophthalmology|November 14, 2020
Reply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous ChorioretinopathyThomas J van Rijssen, Elon H C van Dijk, Greet Dijkman, et al.
Pageof 9